Medicare Program; Virtual Meeting of the Medicare Evidence Development and Coverage Advisory Committee-September 22, 2021, 41040-41041 [2021-16314]
Download as PDF
41040
Federal Register / Vol. 86, No. 144 / Friday, July 30, 2021 / Notices
Dated: July 26, 2021.
William N. Parham, III
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
can be found in the collection’s
supporting statement and associated
materials (see ADDRESSES).
lotter on DSK11XQN23PROD with NOTICES1
Generic Information Collection
1. Type of Information Collection
Request: New collection: Title of
Information Collection: Expressions of
Interest in the Infant Well-Child Visit
Affinity Group; Use: To improve the use
and quality of well-child visits for
Medicaid and CHIP beneficiaries ages 0
to 12 months, CMS has launched the
Infant Well-Child Visit Learning
Collaborative Affinity Group. The
affinity group will provide technical
assistance to state Medicaid and CHIP
agencies and their partners through
group workshops and one-on-one
meetings. Quality improvement (QI)
advisors and subject matter experts will
provide state teams with individualized
guidance, including QI tools, to identify,
implement, and test change ideas to
improve infant well-child visits and
then scale those changes that prove
successful.
Many infants do not receive the
recommended number of infant wellchild visits. Reasons for missing visits
include lack of transportation, work
responsibilities, lack of childcare, and
other social stressors. The COVID–19
pandemic has exacerbated the number
of missed well-child visits, with 21
percent fewer (4.6 million) child
screening services provided between
March through October 2020, compared
to the same period in 2019. Because
Medicaid and CHIP cover nearly 40
percent of all children, focusing on
well-child visits is an opportunity for
state Medicaid and CHIP programs to
improve overall attendance and quality
of infant well-child visits and to reduce
disparities in well-infant care. When
children receive the recommended
number of high-quality visits, they are
more likely to be up-to-date on
immunizations, have developmental
concerns recognized early, and are less
likely to visit the emergency
department. Form Number: CMS–10398
(#72) (OMB control number: 0938–
1148); Frequency: Once; Affected
Public: State, Local, or Tribal
Governments; Number of Respondents:
56; Total Annual Responses: 20; Total
Annual Hours: 140. (For policy
questions regarding this collection
contact Kristen Zycherman at 410–786–
6974.)
VerDate Sep<11>2014
17:24 Jul 29, 2021
Jkt 253001
[FR Doc. 2021–16208 Filed 7–29–21; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3410–N]
Medicare Program; Virtual Meeting of
the Medicare Evidence Development
and Coverage Advisory Committee—
September 22, 2021
Centers for Medicare &
Medicaid Services (CMS), Health and
Human Services (HHS).
ACTION: Notice.
AGENCY:
This notice announces a
virtual public meeting of the Medicare
Evidence Development & Coverage
Advisory Committee (MEDCAC)
(‘‘Committee’’) will be held on
Wednesday, September 22, 2021. The
MEDCAC panel will examine relevant
health outcomes in studies for
cerebrovascular disease treatment with a
particular focus on new technologies of
interest to CMS. Given the increased
emphasis on new and innovative
medical products for treating diseases
that have few proven therapies, studies
on certain medical technologies have
focused on intermediate and surrogate
outcomes rather than longer-term data.
As a result, there are more frequent
evidence gaps with respect to the
clinically meaningful health outcomes
for CMS beneficiaries, and these gaps
impact our assessments of medical
technologies. The MEDCAC panel will
examine the growing challenges
associated with the decreased level of
evidence of certain new and innovative
technologies. By voting on specific
questions, and by their discussions,
MEDCAC panel members will advise
CMS about the ideal health outcomes in
research studies of cerebrovascular
disease treatment technologies,
appropriate measurement instruments
and follow-up durations to help to
provide clarity and transparency of
National Coverage Analyses (NCAs).
This meeting is open to the public in
accordance with the Federal Advisory
Committee Act.
DATES:
Meeting Date: The virtual meeting
will be held on Wednesday, September
SUMMARY:
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
22, 2021 from 8:00 a.m. until 4:30 p.m.,
Eastern Daylight Time (EDT).
Deadline for Submission of Written
Comments: Written comments must be
received at the email address specified
in the ADDRESSES section of this notice
by 5:00 p.m., Eastern Daylight Time
(EDT), on Monday, August 23, 2021.
Once submitted, all comments are final.
Deadlines for Speaker Registration
and Presentation Materials: The
deadline to register to be a speaker and
to submit PowerPoint presentation
materials and writings that will be used
in support of an oral presentation is 5:00
p.m., EDT, on Monday, August 23, 2021.
Speakers may register by phone or via
email by contacting the person listed in
the FOR FURTHER INFORMATION CONTACT
section of this notice. Presentation
materials must be received at the email
address specified in the ADDRESSES
section of this notice.
Submission of Presentations and
Comments: Presentation materials and
written comments that will be presented
at the meeting must be submitted via
email to MedCACpresentations@
cms.hhs.gov section of this notice by
Monday, August 23, 2021.
Deadline for All Other Attendees
Registration: Individuals who want to
join the meeting may register online at
https://cms.zoomgov.com/webinar/
register/WN_
eJmuvv1UTImALOSXqhKmPQ 4:30
p.m. EDT, on Wednesday, September
22, 2021.
Webinar and Teleconference Meeting
Information: Teleconference dial-in
instructions, and related webinar details
will be posted on the meeting agenda,
which will be available on the CMS
website https://www.cms.gov/medicarecoverage-database/indexes/medcacmeetings-index.aspx?bc=
BAAAAAAAAAAA&. Participants in
the MEDCAC meeting will require the
following: A computer, laptop or
smartphone where the Zoom
application needs to be downloaded; a
strong Wi-Fi or an internet connection
and access to use Chrome or Firefox
web browser and a webcam if the
meeting participant is scheduled to
speak or make a presentation during the
meeting.
Deadline for Submitting a Request for
Special Accommodations: Individuals
viewing or listening to the meeting who
are hearing or visually impaired and
have special requirements, or a
condition that requires special
assistance, should send an email to the
MEDCAC Coordinator as specified in
the FOR FURTHER INFORMATION CONTACT
section of this notice no later than 5:00
p.m., EDT on Friday, August 27, 2021.
E:\FR\FM\30JYN1.SGM
30JYN1
Federal Register / Vol. 86, No. 144 / Friday, July 30, 2021 / Notices
Due to the current COVID–
19 public health emergency, the Panel
meeting will be held virtually.
FOR FURTHER INFORMATION CONTACT: Tara
Hall, MEDCAC Coordinator, via email at
Tara.Hall@cms.hhs.gov or by phone
410–786–4347.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
I. Background
MEDCAC, formerly known as the
Medicare Coverage Advisory Committee
(MCAC), is advisory in nature, with all
final coverage decisions resting with
CMS. MEDCAC is used to supplement
CMS’ internal expertise. Accordingly,
the advice rendered by the MEDCAC is
most useful when it results from a
process of full scientific inquiry and
thoughtful discussion, in an open
forum, with careful framing of
recommendations and clear
identification of the basis of those
recommendations. MEDCAC members
are valued for their background,
education, and expertise in a wide
variety of scientific, clinical, and other
related fields. (For more information on
MEDCAC, see the MEDCAC Charter
(https://www.cms.gov/Regulations-andGuidance/Guidance/FACA/Downloads/
medcaccharter.pdf) and the CMS
Guidance Document, Factors CMS
Considers in Referring Topics to the
MEDCAC (https://www.cms.gov/
medicare-coverage-database/details/
medicare-coverage-documentdetails.aspx?MCDId=10).
lotter on DSK11XQN23PROD with NOTICES1
II. Meeting Topic and Format
This notice announces the
Wednesday, September 22, 2021, virtual
public meeting of the Committee. The
MEDCAC panel will examine relevant
health outcomes in studies for
cerebrovascular disease treatment with a
particular focus on new technologies of
interest to CMS. Given the increased
emphasis on new and innovative
medical products for treating diseases
that have few proven therapies, studies
on certain medical technologies have
focused on intermediate and surrogate
outcomes rather than longer-term data.
As a result, there are more frequent
evidence gaps with respect to the
clinically meaningful health outcomes
for CMS beneficiaries, and these gaps
impact our assessments of medical
technologies. The MEDCAC panel will
examine the growing challenges
associated with the decreased level of
evidence of certain new and innovative
technologies. By voting on specific
questions, and by their discussions,
MEDCAC panel members will advise
CMS about the ideal health outcomes in
research studies of cerebrovascular
VerDate Sep<11>2014
17:24 Jul 29, 2021
Jkt 253001
disease treatment technologies,
appropriate measurement instruments
and follow-up durations to help to
provide clarity and transparency of
National Coverage Analyses (NCAs).
Background information about this
topic, including panel materials, is
available at https://www.cms.gov/
medicare-coverage-database/indexes/
medcac-meetings-index.aspx?bc=
BAAAAAAAAAAA&. Electronic copies
of all the meeting materials will be on
the CMS website no later than 2
business days before the meeting. We
encourage the participation of
organizations with expertise in the
appraisal of the state of evidence for the
use of services and technologies to
diagnose and treat patients with
cerebrovascular disease. This meeting is
open to the public. The Committee will
hear oral presentations from the public
for approximately 45 minutes. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than what
can be reasonably accommodated
during the scheduled open public
hearing session, we may conduct a
lottery to determine the speakers for the
scheduled open public hearing session.
The contact person will notify
interested persons regarding their
request to speak by August 30, 2021.
Your comments must focus on issues
specific to the list of topics that we have
proposed to the Committee. The list of
research topics to be discussed at the
meeting will be available on the
following website prior to the meeting:
https://www.cms.gov/medicare-coveragedatabase/indexes/medcac-meetingsindex.aspx?bc=BAAAAAAAAAAA&.
We require that you declare at the
meeting whether you have any financial
involvement with manufacturers (or
their competitors) of any items or
services being discussed. Speakers
presenting at the MEDCAC meeting
must include a full disclosure slide as
their second slide in their presentation
for financial interests (for example, type
of financial association—consultant,
research support, advisory board, and
an indication of level, such as minor
association <$10,000 or major
association >$10,000) as well as
intellectual conflicts of interest (for
example, involvement in a federal or
nonfederal advisory committee that has
discussed the issue) that may pertain in
any way to the subject of this meeting.
If you are representing an organization,
we require that you also disclose
conflict of interest information for that
organization. If you do not have a
PowerPoint presentation, you will need
to present the full disclosure
PO 00000
Frm 00040
Fmt 4703
Sfmt 9990
41041
information requested previously at the
beginning of your statement to the
Committee.
The Committee will deliberate openly
on the topics under consideration.
Interested persons may observe the
deliberations, but the Committee will
not hear further comments during this
time except at the request of the
chairperson. The Committee will also
allow a 15-minute unscheduled open
public session for any attendee to
address issues specific to the topics
under consideration. At the conclusion
of the day, the members will vote and
the Committee will make its
recommendation(s) to CMS.
III. Registration Instructions
CMS’ Coverage and Analysis Group is
coordinating meeting registration. While
there is no registration fee, individuals
must register to attend. You may register
online at https://www.cms.gov/apps/
events/upcomingevents.
asp?strOrderBy=1&type=3 or by phone
by contacting the person listed in the
FOR FURTHER INFORMATION CONTACT
section of this notice by the deadline
listed in the DATES section of this notice.
Please provide your full name (as it
appears on your state-issued driver’s
license), address, organization,
telephone number(s), and email address.
You will receive a registration
confirmation with instructions for your
participation at the virtual public
meeting.
IV. Collection of Information
This document does not impose
information collection requirements,
that is, reporting, recordkeeping or
third-party disclosure requirements.
Consequently, there is no need for
review by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. Chapter 35).
The Chief Medical Officer and
Director of the Center for Clinical
Standards and Quality for the Centers
for Medicare & Medicaid Services
(CMS), Lee A. Fleisher, having reviewed
and approved this document, authorizes
Lynette Wilson, who is the Federal
Register Liaison, to electronically sign
this document for purposes of
publication in the Federal Register.
Dated: July 27, 2021.
Lynette Wilson,
Federal Register Liaison, Centers for Medicare
& Medicaid Services.
[FR Doc. 2021–16314 Filed 7–29–21; 8:45 am]
BILLING CODE 4120–01–P
E:\FR\FM\30JYN1.SGM
30JYN1
Agencies
[Federal Register Volume 86, Number 144 (Friday, July 30, 2021)]
[Notices]
[Pages 41040-41041]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-16314]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-3410-N]
Medicare Program; Virtual Meeting of the Medicare Evidence
Development and Coverage Advisory Committee--September 22, 2021
AGENCY: Centers for Medicare & Medicaid Services (CMS), Health and
Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces a virtual public meeting of the Medicare
Evidence Development & Coverage Advisory Committee (MEDCAC)
(``Committee'') will be held on Wednesday, September 22, 2021. The
MEDCAC panel will examine relevant health outcomes in studies for
cerebrovascular disease treatment with a particular focus on new
technologies of interest to CMS. Given the increased emphasis on new
and innovative medical products for treating diseases that have few
proven therapies, studies on certain medical technologies have focused
on intermediate and surrogate outcomes rather than longer-term data. As
a result, there are more frequent evidence gaps with respect to the
clinically meaningful health outcomes for CMS beneficiaries, and these
gaps impact our assessments of medical technologies. The MEDCAC panel
will examine the growing challenges associated with the decreased level
of evidence of certain new and innovative technologies. By voting on
specific questions, and by their discussions, MEDCAC panel members will
advise CMS about the ideal health outcomes in research studies of
cerebrovascular disease treatment technologies, appropriate measurement
instruments and follow-up durations to help to provide clarity and
transparency of National Coverage Analyses (NCAs). This meeting is open
to the public in accordance with the Federal Advisory Committee Act.
DATES:
Meeting Date: The virtual meeting will be held on Wednesday,
September 22, 2021 from 8:00 a.m. until 4:30 p.m., Eastern Daylight
Time (EDT).
Deadline for Submission of Written Comments: Written comments must
be received at the email address specified in the ADDRESSES section of
this notice by 5:00 p.m., Eastern Daylight Time (EDT), on Monday,
August 23, 2021. Once submitted, all comments are final.
Deadlines for Speaker Registration and Presentation Materials: The
deadline to register to be a speaker and to submit PowerPoint
presentation materials and writings that will be used in support of an
oral presentation is 5:00 p.m., EDT, on Monday, August 23, 2021.
Speakers may register by phone or via email by contacting the person
listed in the FOR FURTHER INFORMATION CONTACT section of this notice.
Presentation materials must be received at the email address specified
in the ADDRESSES section of this notice.
Submission of Presentations and Comments: Presentation materials
and written comments that will be presented at the meeting must be
submitted via email to [email protected] section of this
notice by Monday, August 23, 2021.
Deadline for All Other Attendees Registration: Individuals who want
to join the meeting may register online at https://cms.zoomgov.com/webinar/register/WN_eJmuvv1UTImALOSXqhKmPQ 4:30 p.m. EDT, on Wednesday,
September 22, 2021.
Webinar and Teleconference Meeting Information: Teleconference
dial-in instructions, and related webinar details will be posted on the
meeting agenda, which will be available on the CMS website https://www.cms.gov/medicare-coverage-database/indexes/medcac-meetings-index.aspx?bc=BAAAAAAAAAAA&. Participants in the MEDCAC meeting will
require the following: A computer, laptop or smartphone where the Zoom
application needs to be downloaded; a strong Wi-Fi or an internet
connection and access to use Chrome or Firefox web browser and a webcam
if the meeting participant is scheduled to speak or make a presentation
during the meeting.
Deadline for Submitting a Request for Special Accommodations:
Individuals viewing or listening to the meeting who are hearing or
visually impaired and have special requirements, or a condition that
requires special assistance, should send an email to the MEDCAC
Coordinator as specified in the FOR FURTHER INFORMATION CONTACT section
of this notice no later than 5:00 p.m., EDT on Friday, August 27, 2021.
[[Page 41041]]
ADDRESSES: Due to the current COVID-19 public health emergency, the
Panel meeting will be held virtually.
FOR FURTHER INFORMATION CONTACT: Tara Hall, MEDCAC Coordinator, via
email at [email protected] or by phone 410-786-4347.
SUPPLEMENTARY INFORMATION:
I. Background
MEDCAC, formerly known as the Medicare Coverage Advisory Committee
(MCAC), is advisory in nature, with all final coverage decisions
resting with CMS. MEDCAC is used to supplement CMS' internal expertise.
Accordingly, the advice rendered by the MEDCAC is most useful when it
results from a process of full scientific inquiry and thoughtful
discussion, in an open forum, with careful framing of recommendations
and clear identification of the basis of those recommendations. MEDCAC
members are valued for their background, education, and expertise in a
wide variety of scientific, clinical, and other related fields. (For
more information on MEDCAC, see the MEDCAC Charter (https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/Downloads/medcaccharter.pdf) and
the CMS Guidance Document, Factors CMS Considers in Referring Topics to
the MEDCAC (https://www.cms.gov/medicare-coverage-database/details/medicare-coverage-document-details.aspx?MCDId=10).
II. Meeting Topic and Format
This notice announces the Wednesday, September 22, 2021, virtual
public meeting of the Committee. The MEDCAC panel will examine relevant
health outcomes in studies for cerebrovascular disease treatment with a
particular focus on new technologies of interest to CMS. Given the
increased emphasis on new and innovative medical products for treating
diseases that have few proven therapies, studies on certain medical
technologies have focused on intermediate and surrogate outcomes rather
than longer-term data. As a result, there are more frequent evidence
gaps with respect to the clinically meaningful health outcomes for CMS
beneficiaries, and these gaps impact our assessments of medical
technologies. The MEDCAC panel will examine the growing challenges
associated with the decreased level of evidence of certain new and
innovative technologies. By voting on specific questions, and by their
discussions, MEDCAC panel members will advise CMS about the ideal
health outcomes in research studies of cerebrovascular disease
treatment technologies, appropriate measurement instruments and follow-
up durations to help to provide clarity and transparency of National
Coverage Analyses (NCAs).
Background information about this topic, including panel materials,
is available at https://www.cms.gov/medicare-coverage-database/indexes/medcac-meetings-index.aspx?bc=BAAAAAAAAAAA&. Electronic copies of all
the meeting materials will be on the CMS website no later than 2
business days before the meeting. We encourage the participation of
organizations with expertise in the appraisal of the state of evidence
for the use of services and technologies to diagnose and treat patients
with cerebrovascular disease. This meeting is open to the public. The
Committee will hear oral presentations from the public for
approximately 45 minutes. Time allotted for each presentation may be
limited. If the number of registrants requesting to speak is greater
than what can be reasonably accommodated during the scheduled open
public hearing session, we may conduct a lottery to determine the
speakers for the scheduled open public hearing session. The contact
person will notify interested persons regarding their request to speak
by August 30, 2021. Your comments must focus on issues specific to the
list of topics that we have proposed to the Committee. The list of
research topics to be discussed at the meeting will be available on the
following website prior to the meeting: https://www.cms.gov/medicare-coverage-database/indexes/medcac-meetings-index.aspx?bc=BAAAAAAAAAAA&.
We require that you declare at the meeting whether you have any
financial involvement with manufacturers (or their competitors) of any
items or services being discussed. Speakers presenting at the MEDCAC
meeting must include a full disclosure slide as their second slide in
their presentation for financial interests (for example, type of
financial association--consultant, research support, advisory board,
and an indication of level, such as minor association <$10,000 or major
association >$10,000) as well as intellectual conflicts of interest
(for example, involvement in a federal or nonfederal advisory committee
that has discussed the issue) that may pertain in any way to the
subject of this meeting. If you are representing an organization, we
require that you also disclose conflict of interest information for
that organization. If you do not have a PowerPoint presentation, you
will need to present the full disclosure information requested
previously at the beginning of your statement to the Committee.
The Committee will deliberate openly on the topics under
consideration. Interested persons may observe the deliberations, but
the Committee will not hear further comments during this time except at
the request of the chairperson. The Committee will also allow a 15-
minute unscheduled open public session for any attendee to address
issues specific to the topics under consideration. At the conclusion of
the day, the members will vote and the Committee will make its
recommendation(s) to CMS.
III. Registration Instructions
CMS' Coverage and Analysis Group is coordinating meeting
registration. While there is no registration fee, individuals must
register to attend. You may register online at https://www.cms.gov/apps/events/upcomingevents.asp?strOrderBy=1&type=3 or by phone by contacting
the person listed in the FOR FURTHER INFORMATION CONTACT section of
this notice by the deadline listed in the DATES section of this notice.
Please provide your full name (as it appears on your state-issued
driver's license), address, organization, telephone number(s), and
email address. You will receive a registration confirmation with
instructions for your participation at the virtual public meeting.
IV. Collection of Information
This document does not impose information collection requirements,
that is, reporting, recordkeeping or third-party disclosure
requirements. Consequently, there is no need for review by the Office
of Management and Budget under the authority of the Paperwork Reduction
Act of 1995 (44 U.S.C. Chapter 35).
The Chief Medical Officer and Director of the Center for Clinical
Standards and Quality for the Centers for Medicare & Medicaid Services
(CMS), Lee A. Fleisher, having reviewed and approved this document,
authorizes Lynette Wilson, who is the Federal Register Liaison, to
electronically sign this document for purposes of publication in the
Federal Register.
Dated: July 27, 2021.
Lynette Wilson,
Federal Register Liaison, Centers for Medicare & Medicaid Services.
[FR Doc. 2021-16314 Filed 7-29-21; 8:45 am]
BILLING CODE 4120-01-P